M. Conte

发表

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

G. Tedeschi, A. Gallo, G. Donnarumma, 2022, Journal of Neurology.

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab

G. Tedeschi, A. Gallo, G. Donnarumma, 2021, Neurological Sciences.

Characterizing SARS-CoV-2 transcription of subgenomic and genomic RNAs during early human infection using multiplexed ddPCR

A. Pekosz, H. Mostafa, H. Hwang, 2022, medRxiv.

Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted tissue distribution

R. Zhou, R. Lorenzo-Redondo, R. Ke, 2021, medRxiv.

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

G. Tedeschi, A. Gallo, G. Donnarumma, 2022, Journal of Neurology.

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod

G. Tedeschi, A. Gallo, G. Donnarumma, 2022, Multiple Sclerosis and Related Disorders.

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab

G. Tedeschi, A. Gallo, G. Donnarumma, 2021, Journal of the Neurological Sciences.

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab

G. Tedeschi, A. Gallo, G. Donnarumma, 2022, Neurological Sciences.

Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence

A. Gallo, G. Donnarumma, A. Bisecco, 2023, Neurological Sciences.